170 related articles for article (PubMed ID: 16462768)
21. BRAF and c-kit gene copy number in mutation-positive malignant melanoma.
Willmore-Payne C; Holden JA; Hirschowitz S; Layfield LJ
Hum Pathol; 2006 May; 37(5):520-7. PubMed ID: 16647948
[TBL] [Abstract][Full Text] [Related]
22. Enhanced detection of BRAF-mutants by pre-PCR cleavage of wild-type sequences revealed circulating melanoma cells heterogeneity.
Fusi A; Berdel R; Havemann S; Nonnenmacher A; Keilholz U
Eur J Cancer; 2011 Sep; 47(13):1971-6. PubMed ID: 21570823
[TBL] [Abstract][Full Text] [Related]
23. BRAF mutations in metastatic melanoma: a possible association with clinical outcome.
Kumar R; Angelini S; Czene K; Sauroja I; Hahka-Kemppinen M; Pyrhönen S; Hemminki K
Clin Cancer Res; 2003 Aug; 9(9):3362-8. PubMed ID: 12960123
[TBL] [Abstract][Full Text] [Related]
24. BRAF mutation detection and identification by cycling temperature capillary electrophoresis.
Hinselwood DC; Abrahamsen TW; Ekstrøm PO
Electrophoresis; 2005 Jun; 26(13):2553-61. PubMed ID: 15948220
[TBL] [Abstract][Full Text] [Related]
25. Detection of B-RAF and N-RAS mutations in human melanoma.
Goydos JS; Mann B; Kim HJ; Gabriel EM; Alsina J; Germino FJ; Shih W; Gorski DH
J Am Coll Surg; 2005 Mar; 200(3):362-70. PubMed ID: 15737846
[TBL] [Abstract][Full Text] [Related]
26. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.
Sharma A; Trivedi NR; Zimmerman MA; Tuveson DA; Smith CD; Robertson GP
Cancer Res; 2005 Mar; 65(6):2412-21. PubMed ID: 15781657
[TBL] [Abstract][Full Text] [Related]
27. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).
Carta C; Moretti S; Passeri L; Barbi F; Avenia N; Cavaliere A; Monacelli M; Macchiarulo A; Santeusanio F; Tartaglia M; Puxeddu E
Clin Endocrinol (Oxf); 2006 Jan; 64(1):105-9. PubMed ID: 16402937
[TBL] [Abstract][Full Text] [Related]
28. KIT pathway alterations in mucosal melanomas of the vulva and other sites.
Omholt K; Grafström E; Kanter-Lewensohn L; Hansson J; Ragnarsson-Olding BK
Clin Cancer Res; 2011 Jun; 17(12):3933-42. PubMed ID: 21680547
[TBL] [Abstract][Full Text] [Related]
29. Suppression of BRAF(V599E) in human melanoma abrogates transformation.
Hingorani SR; Jacobetz MA; Robertson GP; Herlyn M; Tuveson DA
Cancer Res; 2003 Sep; 63(17):5198-202. PubMed ID: 14500344
[TBL] [Abstract][Full Text] [Related]
30. RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis.
Dadzie OE; Yang S; Emley A; Keady M; Bhawan J; Mahalingam M
Br J Dermatol; 2009 Feb; 160(2):368-75. PubMed ID: 18945298
[TBL] [Abstract][Full Text] [Related]
31. Inducible BRAF suppression models for melanoma tumorigenesis.
Hoeflich KP; Jaiswal B; Davis DP; Seshagiri S
Methods Enzymol; 2008; 439():25-38. PubMed ID: 18374154
[TBL] [Abstract][Full Text] [Related]
32. Regulation of iNOS by the p44/42 mitogen-activated protein kinase pathway in human melanoma.
Ellerhorst JA; Ekmekcioglu S; Johnson MK; Cooke CP; Johnson MM; Grimm EA
Oncogene; 2006 Jun; 25(28):3956-62. PubMed ID: 16474847
[TBL] [Abstract][Full Text] [Related]
33. Distinct patterns of DNA copy number alterations associate with BRAF mutations in melanomas and melanoma-derived cell lines.
Greshock J; Nathanson K; Medina A; Ward MR; Herlyn M; Weber BL; Zaks TZ
Genes Chromosomes Cancer; 2009 May; 48(5):419-28. PubMed ID: 19226609
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of mutant ras in human melanoma increases invasiveness, proliferation and anchorage-independent growth in vitro and induces tumour formation and cachexia in vivo.
Fujita M; Norris DA; Yagi H; Walsh P; Morelli JG; Weston WL; Terada N; Bennion SD; Robinson W; Lemon M; Maxwell IH; Yohn JJ
Melanoma Res; 1999 Jun; 9(3):279-91. PubMed ID: 10465584
[TBL] [Abstract][Full Text] [Related]
35. [Study of negative feedback between wild-type BRAF or RAFV600E and Mps1 in melanoma].
Zhang L; He C; Bi Y; Liu F; Cui H; Wang J; Song B; Shi R; Yang B; Wang F; Jia Z; Zhao Z; Liu J
Zhonghua Bing Li Xue Za Zhi; 2015 Apr; 44(4):274-7. PubMed ID: 25975913
[TBL] [Abstract][Full Text] [Related]
36. NRASQ61R immunohistochemistry detects both NRASQ61R and KRASQ61R mutations in colorectal cancer.
Jhuang JY; Yuan CT; Lin YL; Cheng ML; Liau JY; Tsai JH
Pathology; 2017 Jun; 49(4):387-390. PubMed ID: 28433252
[TBL] [Abstract][Full Text] [Related]
37. A Murine Model for Metastatic Conjunctival Melanoma.
de Waard NE; Cao J; McGuire SP; Kolovou PE; Jordanova ES; Ksander BR; Jager MJ
Invest Ophthalmol Vis Sci; 2015 Apr; 56(4):2325-33. PubMed ID: 25722211
[TBL] [Abstract][Full Text] [Related]
38. BRAFV600E and NRASQ61R Homogeneity in Melanoma Tumors.
Uguen A; Talagas M; Marcorelles P; De Braekeleer M
J Invest Dermatol; 2016 Jan; 136(1):337-8. PubMed ID: 26763460
[No Abstract] [Full Text] [Related]
39. An integrated multi-molecular sensor for simultaneous BRAF
Dey S; Koo KM; Wang Z; Sina AAI; Wuethrich A; Trau M
Lab Chip; 2019 Feb; 19(5):738-748. PubMed ID: 30624446
[TBL] [Abstract][Full Text] [Related]
40. Melanocytic tumour in a black sheep never exposed to ultraviolet radiation.
Vala H; Pópulo H; Mesquita JR; Esteves F; Santos C; Soares P; Lopes JM
J Comp Pathol; 2012; 146(2-3):160-4. PubMed ID: 21612790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
